A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop). The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.

Trial Details

NCT ID
NCT07771803
Phase
EARLY_PHASE1
Sponsor
Roger Strair
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Soursop tea
Locations (sample)
  • Camden, New Jersey, United States|39.92595,-75.11962

Key Eligibility Criteria

  • Patients with relapsed or refractory AML or MM not on any anti-neoplastic therapy who have exhausted all therapies and have no available therapy.
  • For AML: Quantifiable leukemia cells in blood (patients without circulating AML blasts may participate if they agree to baseline and post-treatment…
  • For MM: Quantifiable M component (SPEP) or serum free light chain abnormality (ratio greater than 10)
  • ECOG PS 0,1, or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →